Form 4: Inmune Bio Reprices Director Stock Options to $1.50

Inmune Bio, Inc. announced a one-time repricing of certain outstanding stock options for Director James Kelly Ganjei, reducing the exercise price to $1.50 per share.

Summary

• Director James Kelly Ganjei's outstanding stock options were repriced on November 18, 2025.
• The exercise price for these options was reduced to $1.50 per share, matching the closing price of Inmune Bio's common stock on The Nasdaq Capital Market on the repricing date.
• The repricing was approved by the Issuer's stockholders and affected options granted under the 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans.
• All other terms and conditions of the repriced options, including vesting schedules and expiration dates, remain in full force and effect.
• The transaction involved the disposition of options with original exercise prices ranging from $3.91 to $24.82 and the acquisition of new options at the $1.50 exercise price for a total of 366,000 underlying common stock shares.

Sentiment

Score: 3

Explanation: The repricing of options from significantly higher strike prices to a much lower current market price ($1.50) reflects poor past stock performance and potential value destruction for shareholders. While it re-incentivizes the director, it's generally viewed negatively by investors as it effectively grants new options at a lower cost, diluting existing shareholder value. The shareholder approval is a positive governance aspect, but the underlying reason for repricing is negative.

Positives

• The repricing aligns the exercise price of existing options with the current market value, potentially re-incentivizing the director.
• Stockholder approval for the repricing indicates adherence to corporate governance and transparency.

Negatives

• Repricing options typically dilutes shareholder value by effectively granting new options at a lower price, especially if the original options were significantly out-of-the-money.
• The company's stock price has fallen significantly from the original option grant prices (e.g., from $24.82 to $1.50), indicating poor past performance.
• This action could be perceived negatively by investors as it benefits management/directors at the expense of existing shareholders.

Risks

• Potential for negative investor sentiment due to the repricing of options, which can be viewed as a transfer of value from shareholders to option holders.
• The significant drop in stock price (implied by the repricing from much higher strike prices to $1.50) indicates underlying business challenges or market perception issues.
• Future stock price appreciation might be necessary to make these repriced options valuable, which is not guaranteed.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the effective date of the repricing and the remaining terms of the options.

Industry Context

Stock option repricing often occurs in industries where company stock performance has significantly underperformed, leading to "underwater" options that no longer serve as an incentive. This practice aims to re-motivate executives and directors by restoring the incentive value of their equity awards, particularly common in volatile sectors or during periods of company-specific market downturns.

Comparison to Industry Standards

• Option repricing is a controversial practice, generally viewed unfavorably by institutional investors and proxy advisory firms (e.g., ISS, Glass Lewis) as it effectively transfers value from shareholders to executives/directors.
• While companies like Apple (2001) and Microsoft (2003) have repriced options, and it's seen in some biotech firms during downturns, best practices often involve shareholder approval and sometimes a "value-for-value" exchange or longer vesting periods to mitigate shareholder dilution concerns.
• The fact that this repricing was approved by stockholders is a positive governance point, but the significant reduction in strike price (e.g., from $24.82 to $1.50) highlights substantial value destruction for existing shareholders.

Corporate Governance

Related Party Transactions

• The repricing of stock options for Director James Kelly Ganjei constitutes a related party transaction, as it involves a transaction between the company and an insider.

Stakeholder Impact

• Shareholders: Potential negative impact due to effective dilution and the perception of value transfer to insiders. The repricing reflects a significant decline in stock value, which is detrimental to existing shareholders.
• Director (James Kelly Ganjei): Positive impact as previously underwater options are now in-the-money or closer to being in-the-money, restoring incentive value.

Next Steps

• The repriced options will become exercisable in accordance with their original vesting schedules.
• The director's continued service with the Issuer is required for vesting.

Key Dates

Recommendation

The repricing of options, while a negative signal about past performance and potentially dilutive, aims to re-incentivize a key director. For existing shareholders, this event alone doesn't necessarily warrant a 'sell' unless the underlying business fundamentals are deteriorating further. It suggests the company is trying to retain and motivate its leadership amidst a challenging stock performance period. A 'hold' recommendation would be appropriate to observe if this re-incentivization translates into improved future performance and stock appreciation, or if the underlying issues persist. A 'buy' would be premature given the negative implications of the repricing itself.

Keywords

Inmune Bio, INMB, Stock Options, Option Repricing, SEC Form 4, Beneficial Ownership, Director Compensation, Equity Incentive Plan, Corporate Governance, Nasdaq Capital Market